BR9810372A - Processo de transferência de ácido nucléico para o interior de células de organismos eucarióticos pluricelulares in vivo, composição, ácido nucléico e campo elétrico, e, produto de combinação - Google Patents

Processo de transferência de ácido nucléico para o interior de células de organismos eucarióticos pluricelulares in vivo, composição, ácido nucléico e campo elétrico, e, produto de combinação

Info

Publication number
BR9810372A
BR9810372A BR9810372-5A BR9810372A BR9810372A BR 9810372 A BR9810372 A BR 9810372A BR 9810372 A BR9810372 A BR 9810372A BR 9810372 A BR9810372 A BR 9810372A
Authority
BR
Brazil
Prior art keywords
nucleic acid
vivo
cells
composition
electric field
Prior art date
Application number
BR9810372-5A
Other languages
English (en)
Inventor
Michel Bureau
Lluis Mir
Daniel Scherman
Original Assignee
Rhone Poulenc Rorer Sa
Roussy Inst Gustave
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9708232A external-priority patent/FR2765241B1/fr
Application filed by Rhone Poulenc Rorer Sa, Roussy Inst Gustave, Centre Nat Rech Scient filed Critical Rhone Poulenc Rorer Sa
Publication of BR9810372A publication Critical patent/BR9810372A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0412—Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
    • A61N1/0416—Anode and cathode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

"PROCESSO DE TRANSFERêNCIA DE áCIDO NUCLéICO PARA O INTERIOR DE CéLULAS DE ORGANISMOS EUCARIóTICOS PLURICELULARES IN VIVO, COMPOSIçãO, áCIDO NUCLéICO E CAMPO ELéTRICO, E, PRODUTO DE COMBINAçãO". A presente invenção refere-se a um aperfeiçoamento da transferência in vivo, para o interior de células de organismos eucarióticos pluricelulares, de ácidos nucleicos ou de ácidos nucleicos associados com produtos que permitem aumentar o rendimento dessas transferências, e à combinação de um ácido nucleico e do processo de transferência de acordo com a invenção para sua utilização na terapia gênica.
BR9810372-5A 1997-06-30 1998-06-30 Processo de transferência de ácido nucléico para o interior de células de organismos eucarióticos pluricelulares in vivo, composição, ácido nucléico e campo elétrico, e, produto de combinação BR9810372A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9708232A FR2765241B1 (fr) 1997-06-30 1997-06-30 Amelioration du transfert d'acide nucleique dans les cellules d'organismes eucaryotes pluricellulaires et combinaison permettant la mise en oeuvre du procede
US6748797P 1997-12-01 1997-12-01
PCT/FR1998/001399 WO1999001157A1 (fr) 1997-06-30 1998-06-30 Amelioration du transfert d'acide nucleique dans les cellules d'organismes eucaryotes pluricellulaires et combinaison permettant la mise en oeuvre du procede

Publications (1)

Publication Number Publication Date
BR9810372A true BR9810372A (pt) 2000-09-05

Family

ID=26233647

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810372-5A BR9810372A (pt) 1997-06-30 1998-06-30 Processo de transferência de ácido nucléico para o interior de células de organismos eucarióticos pluricelulares in vivo, composição, ácido nucléico e campo elétrico, e, produto de combinação

Country Status (16)

Country Link
US (1) US6528315B2 (pt)
EP (1) EP0991425B1 (pt)
JP (1) JP4664450B2 (pt)
KR (1) KR20010020570A (pt)
CN (1) CN1261808A (pt)
AT (1) ATE290403T1 (pt)
AU (1) AU8444698A (pt)
BR (1) BR9810372A (pt)
CA (1) CA2294802A1 (pt)
CZ (1) CZ299638B6 (pt)
DE (1) DE69829287T2 (pt)
HU (1) HUP0004728A3 (pt)
IL (1) IL133708A0 (pt)
NO (1) NO327499B1 (pt)
PL (1) PL337584A1 (pt)
WO (1) WO1999001157A1 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884430B1 (en) 1997-02-10 2005-04-26 Aventis Pharma S.A. Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
DK1023107T3 (da) * 1997-04-03 2006-12-27 Electrofect As Fremgangsmåde til indgivelse af farmaceutiske præparater og nucleinsyrer i skeletmuskulaturen
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
EP1148885A4 (en) * 1999-02-08 2002-05-08 Chiron Corp ELECTRICALLY INDUCED INCREASE IN IMMUNITY AND EFFECTIVENESS OF IN VIVO DNA VACCINES
CA2377565A1 (en) * 1999-06-25 2001-01-04 Genetronics, Inc. High efficiency transfection based on low electric field strength, long pulse length
ES2328446T5 (es) 2000-02-04 2014-02-27 Children's Hospital Research Foundation Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas
CA2402530C (en) 2000-03-13 2014-01-14 Cornell Research Foundation, Inc. Blocking leukocyte emigration and inflammation by interfering with cd99
AU5345901A (en) 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
CA2409603A1 (en) 2000-05-22 2001-11-29 Merck & Company, Inc. System and method for assessing the performance of a pharmaceutical agent delivery system
EP1353723A2 (en) 2000-11-17 2003-10-22 Gendel Limited Ablation of cells using combined electric field and ultrasound therapy
US6821274B2 (en) 2001-03-07 2004-11-23 Gendel Ltd. Ultrasound therapy for selective cell ablation
CN100422210C (zh) 2000-12-28 2008-10-01 Wyeth公司 来自肺炎链球菌的重组防护蛋白质
CA2441476A1 (en) 2001-03-02 2002-09-12 The Rockefeller University Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
WO2003099382A1 (en) 2002-05-23 2003-12-04 Gendel Limited Ablation device
US20040023910A1 (en) * 2001-09-28 2004-02-05 Zhiming Zhang Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2002360540A1 (en) * 2001-12-04 2003-06-17 University Of Southern California Method for intracellular modifications within living cells using pulsed electric fields
SI1479985T1 (sl) 2002-01-17 2017-10-30 Alfa Laval Corporate Ab Potopni uparjalnik, ki vsebuje ploščni toplotni izmenjevalnik in cilindrično ohišje, kjer je nameščen ploščni toplotni izmenjevalnik
FR2836831B1 (fr) * 2002-03-07 2004-06-25 Centre Nat Rech Scient Combinaison chimiotherapie et antisens de la dna demethylase
WO2003075978A2 (en) 2002-03-07 2003-09-18 Merck & Co., Inc. Clinical syringe with electrical stimulation aspects
US20030198625A1 (en) * 2002-04-19 2003-10-23 Genteric, Inc. Electroporation-mediated transfection of the salivary gland
IL165256A0 (en) 2002-05-24 2005-12-18 Schering Corp Neutralizing human anti-igfr antibody
AU2003302337A1 (en) * 2002-12-31 2004-07-29 The Johns Hopkins University Wound healing method and kits
US20050059999A1 (en) * 2003-09-15 2005-03-17 Mongeon Luc R. Delivering genetic material to a stimulation site
EP1763321A4 (en) 2004-04-16 2010-02-17 Critical Care Innovations Inc SYSTEMS AND METHOD FOR ENHANCING ABLATION OF IMAGE-GUIDED FABRIC
US7923251B2 (en) * 2005-02-23 2011-04-12 The Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for avalanche-mediated transfer of agents into cells
US8101169B2 (en) * 2005-02-23 2012-01-24 The Board Of Trustees Of The Leland Stanford Junior University Ocular gene therapy using avalanche-mediated transfection
US8088382B2 (en) 2005-07-05 2012-01-03 Cornell Research Foundation, Inc. Methods of inhibiting transendothelial migration of neutrophils and monocytes with anti-CD99L2 antibodies
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
CN102921102B (zh) 2006-03-03 2015-06-10 基因特伦尼克斯公司 用于治疗在外科切除术后残留在组织中的微小残余肿瘤的装置
WO2008060814A2 (en) 2006-10-19 2008-05-22 Merck & Co., Inc. ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF
AU2007319604B2 (en) 2006-10-19 2011-03-24 Csl Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US8927508B2 (en) * 2007-11-14 2015-01-06 Vgx Pharmaceuticals, Inc. Antibody production elicited by a DNA vaccine delivered by electroporation
US8093043B2 (en) 2008-06-04 2012-01-10 New York University β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
DK2356135T3 (en) 2008-11-05 2017-12-04 Wyeth Llc IMMUNOGEN MULTICOMPONENT COMPOSITION FOR THE PREVENTION OF BETA-HAEMOLYTIC STRUCTURAL TOC (BHS) DISEASE
BR112013004236A2 (pt) 2010-08-23 2016-07-12 Wyeth Llc formulações estáveis de antígenos de neisseria meningitidis rlp2086
ES2728282T3 (es) 2010-09-10 2019-10-23 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9592398B2 (en) 2011-05-12 2017-03-14 Medtronic, Inc. Leadless implantable medical device with osmotic pump
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR101784644B1 (ko) 2012-03-09 2017-10-11 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
KR20180099912A (ko) 2013-09-08 2018-09-05 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
KR20220011796A (ko) 2017-01-31 2022-01-28 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4301794A (en) 1978-10-18 1981-11-24 Robert Tapper Method for iontophoretic treatment
US4411657A (en) 1980-05-19 1983-10-25 Anibal Galindo Hypodermic needle
JPS5810066A (ja) 1981-07-10 1983-01-20 株式会社アドバンス イオントフオレ−ゼ用プラスタ−構造体
US4476004A (en) 1983-04-08 1984-10-09 D.E.P. Systems, Inc. Apparatus for electrofusion of biological particles
US4441972A (en) 1983-04-08 1984-04-10 D.E.P. Systems, Inc. Apparatus for electrofusion of biological particles
US4639244A (en) 1983-05-03 1987-01-27 Nabil I. Rizk Implantable electrophoretic pump for ionic drugs and associated methods
DE3317415A1 (de) 1983-05-13 1984-11-15 Kernforschungsanlage Jülich GmbH, 5170 Jülich Kammer zur behandlung von zellen im elektrischen feld
US4622031A (en) 1983-08-18 1986-11-11 Drug Delivery Systems Inc. Indicator for electrophoretic transcutaneous drug delivery device
US4557723A (en) 1983-08-18 1985-12-10 Drug Delivery Systems Inc. Applicator for the non-invasive transcutaneous delivery of medicament
US4578168A (en) 1984-07-27 1986-03-25 Biotronics Apparatus for fusing live cells with electric fields
US4663292A (en) 1984-12-21 1987-05-05 Wong Daniel T High-voltage biological macromolecule transfer and cell fusion system
US4702732A (en) 1984-12-24 1987-10-27 Trustees Of Boston University Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands
AT385894B (de) 1985-10-04 1988-05-25 Basem Dr Nashef Schlauchfoermige sonde
US5049488A (en) 1985-11-08 1991-09-17 Genentech, Inc. Method and nucleic acid for the preparation of lecithin:cholesterol acyltransferase
US4695547A (en) 1986-04-02 1987-09-22 Jeffrey L. Hilliard Probe for electrofusion, electroporation, or like procedure
US4786277A (en) 1986-11-21 1988-11-22 Trustees Of Boston University Electrodes, electrode assemblies, methods, and systems for tissue stimulation
US5371003A (en) 1987-05-05 1994-12-06 Sandoz Ltd. Electrotransformation process
US5128257A (en) 1987-08-31 1992-07-07 Baer Bradford W Electroporation apparatus and process
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
US5389069A (en) 1988-01-21 1995-02-14 Massachusetts Institute Of Technology Method and apparatus for in vivo electroporation of remote cells and tissue
US5749847A (en) 1988-01-21 1998-05-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
US5547467A (en) 1988-01-21 1996-08-20 Massachusettes Institute Of Technology Method for rapid temporal control of molecular transport across tissue
EP0398960B1 (en) 1988-01-21 1995-12-06 Massachusetts Institute Of Technology Transport of molecules across tissue using electroporation
US5119832A (en) 1989-07-11 1992-06-09 Ravi Xavier Epidural catheter with nerve stimulators
US5124259A (en) 1989-08-23 1992-06-23 Mitsui Toatsu Chemicals, Inc. Method for electroporation
US5236413B1 (en) 1990-05-07 1996-06-18 Andrew J Feiring Method and apparatus for inducing the permeation of medication into internal tissue
US5081990A (en) 1990-05-11 1992-01-21 New York University Catheter for spinal epidural injection of drugs and measurement of evoked potentials
WO1991019529A1 (en) 1990-06-15 1991-12-26 Cortrak Medical, Inc. Drug delivery apparatus and method
US5499971A (en) 1990-06-15 1996-03-19 Cortrak Medical, Inc. Method for iontophoretically delivering drug adjacent to a heart
US5501662A (en) 1992-05-22 1996-03-26 Genetronics, Inc. Implantable electroporation method and apparatus for drug and gene delivery
US5814603A (en) 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
JPH063783A (ja) 1992-06-19 1994-01-14 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
US5304120A (en) 1992-07-01 1994-04-19 Btx Inc. Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
JP3099049B2 (ja) * 1992-07-29 2000-10-16 農林水産省果樹試験場長 電気的細胞融合及び電気的核酸導入のための大量処理用電極
US5273525A (en) * 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5464386A (en) 1992-08-17 1995-11-07 Genetronics, Inc. Transdermal drug delivery by electroincorporation of vesicles
US5688233A (en) 1992-08-17 1997-11-18 Genetronics, Inc. Electronincorporation enhanced transdermal delivery of molecules
US5462520A (en) 1992-08-17 1995-10-31 Genetronics, Inc. Transsurface drug delivery by electrofusion of microbubbles to the tissue surface
US5318514A (en) 1992-08-17 1994-06-07 Btx, Inc. Applicator for the electroporation of drugs and genes into surface cells
JP3351572B2 (ja) 1992-10-05 2002-11-25 井上 聰一 イオンクロマトグラフィーによる分析体の分離・分析方法、イオンクロマトグラフィー用両荷電具備固定相及び多機能液体クロマトグラフィーによる分析体の分離・分析方法
US5468223A (en) 1992-11-30 1995-11-21 C.N.R.S. Paris Electrochemotherapy
FR2703253B1 (fr) 1993-03-30 1995-06-23 Centre Nat Rech Scient Applicateur d'impulsions electriques pour traitement de tissus biologiques.
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5439440A (en) 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
GB9317380D0 (en) * 1993-08-20 1993-10-06 Therexsys Ltd Transfection process
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
DE4341424A1 (de) 1993-12-04 1995-06-08 Bosch Gmbh Robert Kraftstoffeinspritzpumpe
IL108775A (en) 1994-02-25 2003-09-17 Univ Ramot Method for efficient incorporation of molecules into cells
WO1995035389A1 (en) * 1994-06-17 1995-12-28 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method for introduction of genetic material into microorganisms and transformants obtained therewith
CA2194010A1 (en) 1994-06-24 1996-01-04 Ooi Wong Pulsatile delivery systems of biologically active agents using electro voltage pulsing for controlling membrane permeability
IT235163Y1 (it) 1994-10-10 2000-03-31 Ideal Standard Spa Gruppo di tenuta per elementi maschio di stampi per la colatura di apparecchiature igienico-sanitarie
US5641680A (en) * 1994-11-14 1997-06-24 Zhao; Xi Gene transfer apparatus and method for using the same
US5810762A (en) 1995-04-10 1998-09-22 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
WO1996036714A1 (fr) * 1995-05-18 1996-11-21 Takara Shuzo Co., Ltd. Molecule d'acide nucleique pour le traitement de tumeurs malignes de lymphocytes b, procede pour la produire et son utilisation.
WO1997007826A1 (en) 1995-08-29 1997-03-06 Cbr Laboratories, Inc. In vivo electroporation of cells
US5944710A (en) 1996-06-24 1999-08-31 Genetronics, Inc. Electroporation-mediated intravascular delivery
US5944726A (en) 1996-08-23 1999-08-31 Scimed Life Systems, Inc. Stent delivery system having stent securement means
US5960974A (en) 1996-10-03 1999-10-05 Advance Engineered Products Ltd. Intermodal bulk container
JPH10234366A (ja) 1997-02-26 1998-09-08 Hisamitsu Pharmaceut Co Inc エレクトロポレーション用電極及びその製法、それを用いた製剤
DK1023107T3 (da) 1997-04-03 2006-12-27 Electrofect As Fremgangsmåde til indgivelse af farmaceutiske præparater og nucleinsyrer i skeletmuskulaturen
ATE275423T1 (de) * 1997-06-30 2004-09-15 Aventis Pharma Sa Verabreichung der nukleinsäure in den quergestreiften muskel
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
WO1999036563A1 (en) 1998-01-14 1999-07-22 Emed Corporation Electrically mediated cellular expression
CA2337652C (en) 1998-07-13 2013-03-26 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field

Also Published As

Publication number Publication date
CA2294802A1 (fr) 1999-01-14
IL133708A0 (en) 2001-04-30
CZ299638B6 (cs) 2008-10-01
NO996541L (no) 2000-02-17
US6528315B2 (en) 2003-03-04
JP4664450B2 (ja) 2011-04-06
HUP0004728A1 (hu) 2001-04-28
KR20010020570A (ko) 2001-03-15
NO996541D0 (no) 1999-12-29
WO1999001157A1 (fr) 1999-01-14
ATE290403T1 (de) 2005-03-15
HUP0004728A3 (en) 2003-08-28
US20020012914A1 (en) 2002-01-31
DE69829287D1 (de) 2005-04-14
EP0991425A1 (fr) 2000-04-12
CN1261808A (zh) 2000-08-02
DE69829287T2 (de) 2006-04-13
JP2002507984A (ja) 2002-03-12
CZ475499A3 (cs) 2000-07-12
PL337584A1 (en) 2000-08-28
AU8444698A (en) 1999-01-25
EP0991425B1 (fr) 2005-03-09
NO327499B1 (no) 2009-07-20

Similar Documents

Publication Publication Date Title
BR9810372A (pt) Processo de transferência de ácido nucléico para o interior de células de organismos eucarióticos pluricelulares in vivo, composição, ácido nucléico e campo elétrico, e, produto de combinação
BR9810369A (pt) Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação
BG101103A (en) Mammalian telomerase
MX9700270A (es) Composicion que contiene acidos nucleicos, preparacion y utilizacion.
FI962799A (fi) Nukleiinihappoja sisältävä valmiste, sen valmistus ja käyttö
NO973745D0 (no) Nukleinsyreholdig preparat, dets fremstilling og anvendelse
PT980263E (pt) Produto de combinacao que associa um acido nucleico a uma substancia desorganizadora da matriz extracelular para terapia genetica
WO1996001614A3 (en) Rna component of telomerase
AU6194286A (en) New carboxylic acid derivatives, their manufacturing process,use and medicines containing these compounds
BR9407971A (pt) Produto pseudodipeptideo processo químico e enzimático de preparaçao do mesmo aplicaçao do produto e medicamento resultante da aplicaçao
PT998501E (pt) Polimeros cationicos complexos associando os referidos polimeros cationicos e substancias terapeuticamente activas compreendendo pelo menos uma carga negativa especialmente acidos nucleicos e sua utilizacao em terapia genica
KR0148213B1 (en) Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same
WO1995003406A3 (en) Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens
IL137247A0 (en) Transfecting compositions sensitive to reducing conditions, pharmaceutical compositions containing them, and their applications
GT199900014A (es) Gen de streptomyces avermilitis que dirige la relacion de avermectinas b2: b1.
AU6113098A (en) Compositions for treatment of disorders involving programmed cell death
BR9712210A (pt) Processos de preparação de uma composição para a transferência de ácidos nucléicos e para a transferência de ácido nucléico em células in vitro ou ex vivo, e, composição para a transferência de ácidos nucléicos.
BR9909044A (pt) Vetor de tranferência de ácidos nucleicos, composição, utilização de um vetor de tranferência de ácidos nucleicos, processos de transfecção de ácidos nucleicos nas células, e de tratamento de doenças, e, célula recombinante
UA10420A (uk) Аhтиалкогольhий та аhтиhаркотичhий засіб
IT212103Z2 (it) Targhetta metallica munita posteriormente di pernetti cavi per lasua applicazione sulla pianta delle suole delle calzature

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A,8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1909 DE 07/08/2007.